3 Things In Biotech, April 20: AstraZeneca Re-Enters The Big Leagues, Aduro Looks Ahead, Lilly Looks Close

AstraZeneca starts the big fight in EGFR-positive lung cancer. Aduro teed up a new antibody therapy at AACR. Lilly gets its materials for a big meeting with the AAC. Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at ...